Back to top
more

Regulus Therapeutics (RGLS)

(Real Time Quote from BATS)

$2.28 USD

2.28
67,474

+0.06 (2.70%)

Updated Apr 25, 2024 02:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More

Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.

Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study

Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.

Regulus (RGLS) Surges on Enrollment Completion for RGLS8429

Regulus (RGLS) surges as it completes enrollment in the first cohort to evaluate RGLS8429 for kidney disease.

Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study

Regulus Therapeutics (RGLS) reports positive top-line data from a phase I single-dose ascending study of its lead candidate RGLS8429 in autosomal dominant polycystic kidney disease.

Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug

The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.

Regulus (RGLS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Regulus (RGLS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates

Regulus (RGLS) delivered earnings and revenue surprises of -42.86% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Regulus (RGLS) to Report a Decline in Earnings: What to Look Out for

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates

Regulus (RGLS) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Do Options Traders Know Something About Regulus Therapeutics (RGLS) Stock We Don't?

Investors need to pay close attention to Regulus Therapeutics (RGLS) stock based on the movements in the options market lately.

Regulus (RGLS) Reports Q1 Loss, Misses Revenue Estimates

Regulus (RGLS) delivered earnings and revenue surprises of 11.11% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates

Zoetis (ZTS) beat estimates for both earnings and revenues in the first quarter of 2021.

Will Regulus (RGLS) Report Negative Q4 Earnings? What You Should Know

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock?

Investors need to pay close attention to Regulus Therapeutics (RGLS) stock based on the movements in the options market lately.

Regulus (RGLS) Reports Q3 Loss, Tops Revenue Estimates

Regulus (RGLS) delivered earnings and revenue surprises of 80.00% and 880.39%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regulus (RGLS) Reports Q2 Loss, Lags Revenue Estimates

Regulus (RGLS) delivered earnings and revenue surprises of -9.52% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regulus (RGLS) Expected to Beat Earnings Estimates: Should You Buy?

Regulus (RGLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates

Regulus (RGLS) delivered earnings and revenue surprises of 10.34% and -10.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates

Regulus (RGLS) delivered earnings and revenue surprises of 50.00% and -99.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Regulus (RGLS) Report Negative Q2 Earnings? What You Should Know

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.